Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigations

PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models

Thijs H. Oude Munnink, Marlous E.A. Arjaans, Hetty Timmer-Bosscha, Carolina P. Schröder, Jan W. Hesselink, Silke R. Vedelaar, Annemiek M.E. Walenkamp, Michael Reiss, Richard C. Gregory, Marjolijn N. Lub-de Hooge and Elisabeth G.E. de Vries
Journal of Nuclear Medicine December 2011, 52 (12) 2001-2008; DOI: https://doi.org/10.2967/jnumed.111.092809
Thijs H. Oude Munnink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marlous E.A. Arjaans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hetty Timmer-Bosscha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina P. Schröder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan W. Hesselink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silke R. Vedelaar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annemiek M.E. Walenkamp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Reiss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard C. Gregory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjolijn N. Lub-de Hooge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth G.E. de Vries
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 52 no. 12 2001-2008
DOI 
https://doi.org/10.2967/jnumed.111.092809
PubMed 
22072706

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 6, 2011
  • Accepted for publication July 14, 2011
  • Published online December 5, 2011.

Article Versions

  • previous version (November 9, 2011 - 06:45).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2011 by Society of Nuclear Medicine

Author Information

  1. Thijs H. Oude Munnink1,
  2. Marlous E.A. Arjaans1,
  3. Hetty Timmer-Bosscha1,
  4. Carolina P. Schröder1,
  5. Jan W. Hesselink1,
  6. Silke R. Vedelaar1,
  7. Annemiek M.E. Walenkamp1,
  8. Michael Reiss2,
  9. Richard C. Gregory3,
  10. Marjolijn N. Lub-de Hooge4,5 and
  11. Elisabeth G.E. de Vries1
  1. 1Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands
  2. 2Departments of Medicine, Molecular Genetics, Microbiology, and Immunology, Robert Wood Johnson Medical School and Cancer Institute of New Jersey, New Brunswick, New Jersey
  3. 3Oncology Research, Genzyme Corporation, Framingham, Massachusetts
  4. 4Department of Nuclear Medicine and Molecular Imaging, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands; and
  5. 5Department of Hospital and Clinical Pharmacy, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands
  1. For correspondence or reprints contact: Elisabeth G.E. de Vries, Department of Medical Oncology, University Medical Center Groningen, P.O. Box 30.001, 9700RB Groningen, The Netherlands. E-mail: e.g.e.de.vries{at}int.umcg.nl
View Full Text

Statistics from Altmetric.com

Cited By...

  • 50 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
    Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub-de Hooge, Annelies Jorritsma-Smit, Ronald Boellaard, Iris C. Kok, Sjoukje F. Oosting, Carolina P. Schröder, T. Jeroen N. Hiltermann, Anthonie J. van der Wekken, Harry J. M. Groen, Thomas C. Kwee, Sjoerd G. Elias, Jourik A. Gietema, Sandra Sanabria Bohorquez, Alex de Crespigny, Simon-Peter Williams, Christoph Mancao, Adrienne H. Brouwers, Bernard M. Fine, Elisabeth G. E. de Vries
    Nature Medicine 2018 24 12
  • ImmunoPET: Concept, Design, and Applications
    Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, Gang Huang, Quan-Yong Luo, Weibo Cai
    Chemical Reviews 2020 120 8
  • PET imaging with 89Zr: From radiochemistry to the clinic
    Melissa A. Deri, Brian M. Zeglis, Lynn C. Francesconi, Jason S. Lewis
    Nuclear Medicine and Biology 2013 40 1
  • Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
    Scott M. Knowles, Anna M. Wu
    Journal of Clinical Oncology 2012 30 31
  • Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
    Jay Tibbitts, David Canter, Ryan Graff, Alison Smith, Leslie A. Khawli
    mAbs 2016 8 2
  • Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
    Melissa A. Deri, Shashikanth Ponnala, Brian M. Zeglis, Gabor Pohl, J. J. Dannenberg, Jason S. Lewis, Lynn C. Francesconi
    Journal of Medicinal Chemistry 2014 57 11
  • p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for 89Zr ImmunoPET
    Melissa A. Deri, Shashikanth Ponnala, Paul Kozlowski, Benjamin P. Burton-Pye, Huseyin T. Cicek, Chunhua Hu, Jason S. Lewis, Lynn C. Francesconi
    Bioconjugate Chemistry 2015 26 12
  • Advances in phage display technology for drug discovery
    Kobra Omidfar, Maryam Daneshpour
    Expert Opinion on Drug Discovery 2015 10 6
  • 89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges
    Gabriel Fischer, Uwe Seibold, Ralf Schirrmacher, Björn Wängler, Carmen Wängler
    Molecules 2013 18 6
  • New Developments on the Treatment of Liver Fibrosis
    Yukinori Koyama, Jun Xu, Xiao Liu, David A. Brenner
    Digestive Diseases 2016 34 5

Article usage

Article usage: November 2011 to April 2025

AbstractFullPdf
Nov 2011333048
Dec 20116912272
Jan 20122101524
Feb 20121822834
Mar 20121211319
Apr 20121002120
May 20121011824
Jun 2012771725
Jul 2012642834
Aug 2012472934
Sep 2012773030
Oct 2012491918
Nov 2012653826
Dec 2012593217
Jan 2013612731
Feb 2013603918
Mar 2013381519
Apr 2013511925
May 2013453320
Jun 2013321210
Jul 2013211315
Aug 2013421520
Sep 2013381619
Oct 2013312517
Nov 2013252422
Dec 2013261510
Jan 2014202010
Feb 2014222012
Mar 2014243716
Apr 2014111212
May 2014353932
Jun 20143076
Jul 2014241517
Aug 2014676
Sep 2014211923
Oct 2014291213
Nov 201420823
Dec 2014151217
Jan 2015271219
Feb 2015211211
Mar 2015352414
Apr 201535179
May 2015392224
Jun 2015162421
Jul 2015201422
Aug 20151183
Sep 2015131013
Oct 20158126
Nov 20158712
Dec 2015391413
Jan 201647815
Feb 2016211018
Mar 2016271132
Apr 2016272425
May 2016261126
Jun 2016151324
Jul 201612835
Aug 201614812
Sep 20161289
Oct 201622917
Nov 201615719
Dec 20162699
Jan 2017121012
Feb 20177128
Mar 2017232027
Apr 201714216
May 2017181536
Jun 201711145
Jul 201761618
Aug 201752110
Sep 20179912
Oct 2017111915
Nov 2017232111
Dec 20171097
Jan 201816910
Feb 2018201410
Mar 2018171717
Apr 2018131311
May 2018121914
Jun 201810226
Jul 20187123
Aug 20181797
Sep 20181389
Oct 201811138
Nov 20189109
Dec 2018758
Jan 2019934
Feb 2019978
Mar 2019101511
Apr 20191457
May 20191457
Jun 201910915
Jul 2019101214
Aug 2019838
Sep 2019589
Oct 2019101912
Nov 20196713
Dec 20199813
Jan 20201278
Feb 202081413
Mar 202018108
Apr 202041512
May 2020111620
Jun 202012616
Jul 2020111115
Aug 202091110
Sep 20205617
Oct 2020172123
Nov 2020201018
Dec 202031524
Jan 202182225
Feb 202182024
Mar 202132923
Apr 202102914
May 202142417
Jun 20212257
Jul 202172115
Aug 202121521
Sep 202152129
Oct 202142053
Nov 202132431
Dec 202154027
Jan 2022102412
Feb 202293236
Mar 2022102214
Apr 202241111
May 202242021
Jun 202232528
Jul 202272813
Aug 202242720
Sep 202282319
Oct 202263110
Nov 2022103813
Dec 202263218
Jan 202394112
Feb 2023122214
Mar 20236299
Apr 2023121810
May 202341713
Jun 20232178
Jul 202332422
Aug 20237199
Sep 202331210
Oct 20235227
Nov 202382715
Dec 2023103012
Jan 2024422913
Feb 20249237
Mar 2024182937
Apr 20241710526
May 2024204913
Jun 2024211810
Jul 2024253220
Aug 2024282918
Sep 2024321916
Oct 2024303319
Nov 2024403215
Dec 2024403817
Jan 2025244513
Feb 2025129216
Mar 2025224533
Apr 2025216420
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (12)
Journal of Nuclear Medicine
Vol. 52, Issue 12
December 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
Thijs H. Oude Munnink, Marlous E.A. Arjaans, Hetty Timmer-Bosscha, Carolina P. Schröder, Jan W. Hesselink, Silke R. Vedelaar, Annemiek M.E. Walenkamp, Michael Reiss, Richard C. Gregory, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries
Journal of Nuclear Medicine Dec 2011, 52 (12) 2001-2008; DOI: 10.2967/jnumed.111.092809

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
Thijs H. Oude Munnink, Marlous E.A. Arjaans, Hetty Timmer-Bosscha, Carolina P. Schröder, Jan W. Hesselink, Silke R. Vedelaar, Annemiek M.E. Walenkamp, Michael Reiss, Richard C. Gregory, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries
Journal of Nuclear Medicine Dec 2011, 52 (12) 2001-2008; DOI: 10.2967/jnumed.111.092809
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Colocalized targeting of TGF-{beta} and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
  • TGF-{beta} Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
  • PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
  • Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics
  • Placental Growth Factor (PlGF)-Specific Uptake in Tumor Microenvironment of 89Zr-Labeled PlGF Antibody RO5323441
  • Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
  • Molecular Imaging of Tumors with Radioactive Labeled Antibodies from Laboratory to the Clinic
  • Google Scholar

More in this TOC Section

  • How Sensitive Is the Upper Gastrointestinal Tract to 90Y Radioembolization? A Histologic and Dosimetric Analysis in a Porcine Model
  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
  • Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire